ESTRO 2025 - Abstract Book

S2001

Clinical - Urology

ESTRO 2025

Conclusion: While toxicity-minimizing radiotherapy in online adaptive MRI-guided SBRT for PCa was borderline feasible in 2 of the 3 institutes, application of a gating strategy will likely result in more robust coverage of the GTV and CTV.

Keywords: Prostate cancer, Dose de-escalation, MR-linac

2467

Proffered Paper Combining SBRT and durvalumab in hormone-sensitive prostate cancer with oligorecurrent metastases: a randomized phase II trial (POSTCARD GETUG P13) Laure Hily 1 , Maximilien Rogé 1,2 , Dominique Heymann 3 , Yoann Pointreau 4 , Paul Sargos 5 , Emmanuel Meyer 6 , Ulrike Schick 7 , Ali Hasbini 8 , Guillaume Bera 9 , Magali Quivrin 10 , Igor Latorzeff 11 , Valentine Guimas 1 , Pascal Pommier 12 , Thomas Leroy 13 , Philippe Ronchin 14 , Alexis Lepinoy 15 , Audrey Grand 16 , Lysian Cartier 17 , Ossama Didas 18 , Vincent Libois 19 , Denis Cochonneau 3 , Emilie Ollivier 3 , Audrey Blanc-Lapierre 20 , Stéphane Supiot 1 1 Radiation oncology, Institut de cancérologie de l'Ouest, Nantes, France. 2 Radiation oncology, Centre Béquereluerel, Rouen, France. 3 Biopathology, Institut de cancérologie de l'Ouest, Nantes, France. 4 Radiation oncology, Centre Jean Bernard, Le Mans, France. 5 Radiation oncology, Institut Bergonié, Bordeaux, France. 6 Radiation oncology, Centre Baclesse, Caen, France. 7 Radiation oncology, CHU Brest, Brest, France. 8 Radiation oncology, Clinique Pasteur, Brest, France. 9 Radiation oncology, CH Lorient, Lorien, France. 10 Radiation oncology, Centre Leclercq, Dijon, France. 11 Radiation oncology, Clinique Pasteur, Toulouse, France. 12 Radiation oncology, Centre Léon Bérard, Lyon, France.